UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial

Cancer, 2018-10, Vol.124 (20), p.4032-4043

2018

Volltextzugriff (PDF)

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2018-04, Vol.378 (14), p.1277-1290

2018

Volltextzugriff (PDF)

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial

The lancet oncology, 2019-02, Vol.20 (2), p.297-310

2019

Volltextzugriff (PDF)

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

The lancet oncology, 2019-10, Vol.20 (10), p.1370-1385

2019

Volltextzugriff (PDF)

TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5610-5610

2023

Volltextzugriff (PDF)

EVOKE-01: A phase 3 study of sacituzumab govitecan (SG) versus docetaxel in patients with non–small cell lung cancer (NSCLC) progressing on or after platinum-based chemotherapy and checkpoint inhibitors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS9149-TPS9149

2022

Volltextzugriff (PDF)

EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non–small cell lung cancer (NSCLC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS9146-TPS9146

2022

Volltextzugriff (PDF)

PPD01.06 Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-2 Study

Journal of thoracic oncology, 2024-07, Vol.19 (7), p.e6-e7

2024

Volltextzugriff (PDF)

Association of angiotensin-converting enzyme gene dimorphisms with severity of lupus disease

Saudi journal of kidney diseases and transplantation, 2008-09, Vol.19 (5), p.761-766

2008

Volltextzugriff (PDF)

Herpes simplex encephalitis: analysis of 68 cases from a tertiary care hospital in Karachi, Pakistan

Journal of the Pakistan Medical Association, 2005-04, Vol.55 (4), p.146-148

2005

Volltextzugriff (PDF)

An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC)

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.TPS157-TPS157

2021

Volltextzugriff (PDF)

Abstract 4396: TROP2 expression in non-small cell lung cancer

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.4396-4396

2023

Volltextzugriff (PDF)

Consistent efficacy of nivolumab plus ipilimumab across number of International Metastatic Database Consortium (IMDC) risk factors in CheckMate 214

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.4575-4575

2019

Volltextzugriff (PDF)

P7-9. Pembrolizumab +- sacituzumab govitecan for 1L metastatic NSCLC : KEYNOTE-D46 / EVOKE-03 study

Japanese Journal of Lung Cancer, 2023-10, Vol.63 (5), p.587-587

2023

Volltextzugriff (PDF)

Daily rounds on inpatient oncology floor by inpatient hospitalist oncologist and reduced length of stay

Journal of clinical oncology, 2014-10, Vol.32 (30_suppl), p.228-228

2014

Volltextzugriff (PDF)

Platypnea-orthodeoxia: Report of two cases and review of the literature

Southern medical journal (Birmingham, Ala.), 2004-07, Vol.97 (7), p.657-662

2004

Volltextzugriff (PDF)

A phase I/II, two-part, multicenter, first-in-human study of DS-7300a in patients with advanced solid malignant tumors

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS3646-TPS3646

2020

Volltextzugriff (PDF)

Abstract CT067: Pembrolizumab with and without sacituzumab govitecan as first-line treatment for metastatic non-small-cell lung cancer (NSCLC) with PD-L1 TPS ≥50%: phase 3 KEYNOTE-D46/EVOKE-03 study

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT067-CT067

2023

Volltextzugriff (PDF)

Abstract PD1-09: Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD1-09-PD1-09

2021

Volltextzugriff (PDF)

Downregulation of glutathione transferase π sensitizes lymphoma/leukaemia cells to platinum‐based chemotherapy

British journal of haematology, 2013-07, Vol.162 (1), p.135-137

2013

Volltextzugriff (PDF)

Characterization of the benefit-risk profile of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced renal cell carcinoma (aRCC; CheckMate 214)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.686-686

2018

Volltextzugriff (PDF)

CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.4513-4513

2019

Volltextzugriff (PDF)

Abstract OT1-07-06: Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.OT1-07-06-OT1-07-06

2020

Volltextzugriff (PDF)

Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate 214 trial

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3073-3073

2018

Volltextzugriff (PDF)

Analysis of Using Low Dose 3 Factor PCC (Bebulin®) for INR Reversal in Patients with Warfarin Induced Severe/Life-Threatening Bleeding

Blood, 2014-12, Vol.124 (21), p.5043-5043

2014

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(36)

Sprache

Englisch
(35)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(9)
Life Sciences & Biomedicine
(7)
Science & Technology
(7)
Male
(6)
Female
(4)
Immunotherapy
(4)
Monoclonal Antibodies
(4)
Patients
(4)
Targeted Cancer Therapy
(4)
Adult
(3)
Aged
(3)
Aged, 80 And Over
(3)
Clear Cell-Type Renal Cell Carcinoma
(3)
Hospitals
(3)
Inhibitor Drugs
(3)
Kidney Cancer
(3)
Metastasis
(3)
Middle Aged
(3)
Oncology
(3)
Pakistan
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC)

EVOKE-01: A phase 3 study of sacituzumab govitecan (SG) versus docetaxel in patients with non–small cell lung cancer (NSCLC) progressing on or after platinum-based chemotherapy and checkpoint inhibitors

EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non–small cell lung cancer (NSCLC)

PPD01.06 Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-2 Study

Association of angiotensin-converting enzyme gene dimorphisms with severity of lupus disease

Herpes simplex encephalitis: analysis of 68 cases from a tertiary care hospital in Karachi, Pakistan

An open-label, phase II study of patritumab deruxtecan (HER3-DXd, U3-1402) in patients (pts) with previously treated advanced/metastatic colorectal cancer (CRC)

Abstract 4396: TROP2 expression in non-small cell lung cancer

Consistent efficacy of nivolumab plus ipilimumab across number of International Metastatic Database Consortium (IMDC) risk factors in CheckMate 214

P7-9. Pembrolizumab +- sacituzumab govitecan for 1L metastatic NSCLC : KEYNOTE-D46 / EVOKE-03 study

Daily rounds on inpatient oncology floor by inpatient hospitalist oncologist and reduced length of stay

Platypnea-orthodeoxia: Report of two cases and review of the literature

A phase I/II, two-part, multicenter, first-in-human study of DS-7300a in patients with advanced solid malignant tumors

Abstract CT067: Pembrolizumab with and without sacituzumab govitecan as first-line treatment for metastatic non-small-cell lung cancer (NSCLC) with PD-L1 TPS ≥50%: phase 3 KEYNOTE-D46/EVOKE-03 study

Abstract PD1-09: Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal growth factor receptor 3 (HER3)-directed antibody drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC)

Downregulation of glutathione transferase π sensitizes lymphoma/leukaemia cells to platinum‐based chemotherapy

Characterization of the benefit-risk profile of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced renal cell carcinoma (aRCC; CheckMate 214)

CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features

Abstract OT1-07-06: Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease

Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate 214 trial

Analysis of Using Low Dose 3 Factor PCC (Bebulin®) for INR Reversal in Patients with Warfarin Induced Severe/Life-Threatening Bleeding

Suchergebnisse filtern